AI team at In­sil­i­co gets some ma­jor league back­ing from Chi­na as Alex Zha­voronkov builds glob­al net­work

Some of Asia’s top biotech in­vestors are back­ing Alex Zha­voronkov’s AI shop at In­sil­i­co Med­i­cine.

It’s a long way from a megaround, falling in­to an un­spec­i­fied slot in the $5 mil­lion to $10 mil­lion range, but Zha­voronkov has al­lied him­self with some of the most in­ter­est­ing peo­ple in drug de­vel­op­ment. And he’s us­ing this new mon­ey to ex­pand his glob­al net­work of AI ex­perts as he im­me­di­ate­ly be­gins to go af­ter a new raise to back a big­ger game plan.

Ge Li

This new round is led by WuXi AppTec, the high-fly­ing dis­cov­ery and de­vel­op­ment out­fit based in Shang­hai and helmed by Ge Li, who of­fered an in­flu­en­tial shout out by not­ing that the two com­pa­nies share a “mu­tu­al vi­sion that ar­ti­fi­cial in­tel­li­gence and ma­chine learn­ing will op­ti­mize the drug dis­cov­ery process by in­creas­ing the prob­a­bil­i­ty of suc­cess at the pre-clin­i­cal lev­el.”

Sin­ga­pore’s Temasek al­so got in­volved, along with Pe­ter Dia­man­dis’ — of X Prize fame — BOLD Cap­i­tal. Longevi­ty biotech Ju­ve­nes­cence, backed by UK bil­lion­aire Jim Mel­lon and al­lied with Zha­voronkov’s AI op­er­a­tion, al­so came back to chip in­to the round.

“We have col­lab­o­rat­ed with WuXi for over a year now,” Zha­voronkov tells me, “we know them.”

Be­fore Ge Li and his col­leagues de­cid­ed to back the AI shop, he ex­plained in a pre­view to the an­nounce­ment, they start­ed out a year ago val­i­dat­ing their work us­ing known path­ways. Zha­voronkov has been us­ing ma­chine learn­ing to build mol­e­cules, and he start­ed out by prov­ing that he could do it on projects with well un­der­stood bi­ol­o­gy. Now that they’ve passed that test, WuXi and In­sil­i­co are go­ing in­to vir­gin ter­ri­to­ry, build­ing new mol­e­cules aimed at or­phan tar­gets “from scratch” us­ing a neur­al net­work as they build a new dis­cov­ery plat­form with WuXi’s top chemists.

Zha­voronkov poured every­thing he has in­to the com­pa­ny to get it start­ed, and these grow­ing in­ter­na­tion­al con­nec­tions are cen­tral to build­ing the com­pa­ny. In­sil­i­co now has 52 staffers spread from new of­fices in Rockville, MD in­to Eu­rope, Rus­sia and Asia, where a team of 6 work in Tai­wan. His next step, he says, is aimed right at the ex­plod­ing Chi­nese mar­ket.

In AI, he says, “if you’re not in Chi­na now, you’re not go­ing to ex­ist.”

In the mean­time, he’s fo­cused on build­ing his busi­ness de­vel­op­ment team, look­ing to re­cruit some new play­ers.

AI shops have been boom­ing is a va­ri­ety of big op­er­a­tions con­sid­er the ways the tech­nol­o­gy can be used to stream­line drug de­vel­op­ment and im­prove odds of suc­cess — a propo­si­tion that still has a con­sid­er­able ways to go be­fore we start see­ing how it can af­fect the out­put of new drugs that go in­to hu­man test­ing. For big com­pa­nies deeply en­gaged in dis­cov­ery, though, it re­mains a com­pelling ap­proach to pipeline build­ing.

Just a few weeks ago Zha­voronkov al­lied with George Church on a col­lab­o­ra­tion mix­ing Neb­u­la Ge­nomics’ blockchain work with his deep learn­ing ex­perts to build a new plat­form for health­care da­ta. And he con­tin­ues to build re­la­tions with some of the most close­ly watched de­vel­op­ers in the in­dus­try, in­clud­ing Glax­o­SmithK­line.


Im­age: Alex Zha­voronkov. HEALTH TECH­NOLO­GIES TV via YOUTUBE

BiTE® Plat­form and the Evo­lu­tion To­ward Off-The-Shelf Im­muno-On­col­o­gy Ap­proach­es

Despite rapid advances in the field of immuno-oncology that have transformed the cancer treatment landscape, many cancer patients are still left behind.1,2 Not every person has access to innovative therapies designed specifically to treat his or her disease. Many currently available immuno-oncology-based approaches and chemotherapies have brought long-term benefits to some patients — but many patients still need other therapeutic options.3

Fangliang Zhang (Imaginechina via AP Images)

The big mon­ey: Poised to make drug R&D his­to­ry, a Chi­na biotech un­veils uni­corn rac­ing am­bi­tions in a bid to raise $350M-plus on Nas­daq

Almost exactly three years after Shanghai-based Legend came out of nowhere to steal the show at ASCO with jaw-dropping data on their BCMA-targeted CAR-T for multiple myeloma, the little player with Big Pharma connections is taking a giant step toward making it big on Wall Street. And this time they want to seal the deal on a global rep after staking out a unicorn valuation in what’s turned out to be a bull market for biotech IPOs — in the middle of a pandemic.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Jean-Jacques Bienaime, BioMarin chairman and CEO

Bio­Marin holds the line on bleeds with 4-year val­rox up­date on he­mo­phil­ia A — but what's this about an­oth­er de­cline in Fac­tor 8 lev­els?

BioMarin has posted some top-line results for their 4-year followup on the most advanced gene therapy for hemophilia A — extending its streak on keeping a handful of patients free of bleeds and off Factor VIII therapy, but likely stirring fresh worries over a continued drop in Factor VIII levels.

We just don’t know how big a drop.

We’ll see more data when the results are presented at the World Federation of Hemophilia in a couple of weeks. But in a statement out Sunday night, BioMarin $BMRN reported that none of the patients required Factor VIII treatment, adding:

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,900+ biopharma pros reading Endpoints daily — and it's free.

As­traZeneca trum­pets the 'mo­men­tous' da­ta they found for Tagris­so in an ad­ju­vant set­ting for NSCLC — but many of the ex­perts aren’t cheer­ing along

AstraZeneca is rolling out the big guns this evening to provide a salute to their ADAURA data on Tagrisso at ASCO.

Cancer R&D chief José Baselga calls the disease-free survival data for their drug in an adjuvant setting of early stage, epidermal growth factor receptor-mutated NSCLC patients following surgery “momentous.” Roy Herbst, the principal investigator out of Yale, calls it “transformative.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,900+ biopharma pros reading Endpoints daily — and it's free.

Pablo Legorreta, founder and CEO of Royalty Pharma AG, speaks at the annual Milken Institute Global Conference in Beverly Hills, California (Patrick T. Fallon/Bloomberg via Getty Images)

Cap­i­tal­iz­ing Pablo: The world’s biggest drug roy­al­ty buy­er is go­ing pub­lic. And the low-key CEO di­vulges a few se­crets along the way

Pablo Legorreta is one of the most influential players in biopharma you likely never heard of.

Over the last 24 years, Legorreta’s Royalty Pharma group has become, by its own reckoning, the biggest buyer of drug royalties in the world. The CEO and founder has bought up a stake in a lengthy list of the world’s biggest drug franchises, spending $18 billion in the process — $2.2 billion last year alone. And he’s become one of the best-paid execs in the industry, reaping $28 million from the cash flow last year while reserving 20% of the cash flow, less expenses, for himself.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,900+ biopharma pros reading Endpoints daily — and it's free.

Lynn Seely, Myovant CEO

My­ovant’s re­l­u­golix wins a piv­otal prostate can­cer show­down with an old stan­dard — com­ing down to the wire on ap­provals

Myovant $MYOV has rounded the final turn in its development race to get relugolix down to the regulatory wire at the FDA. And the biotech joined the virtual crowd at ASCO with the kind of data needed to keep the investor crowd’s attention.

Much of the attention on the drug has been focused on uterine fibroids, where AbbVie just scored a regulatory win for their rival drug Oriahnn (elagolix) as the biotech posted results in prostate cancer at the ASCO meeting.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,900+ biopharma pros reading Endpoints daily — and it's free.

Dan O'Day, Gilead CEO (Andrew Harnik, AP Images)

Gilead leas­es part­ner rights to TIG­IT, PD-1 in a $2B deal with Ar­cus. Now comes the hard part

Gilead CEO Dan O’Day has brokered his way to a PD-1 and lined up a front row seat in the TIGIT arena, inking a deal worth close to $2 billion to align the big biotech closely with Terry Rosen’s Arcus. And $375 million of that comes upfront, with cash for the buy-in plus equity, along with $400 million for R&D and $1.22 billion in reserve to cover opt-in payments and milestones..

Hotly rumored for weeks, the 2 players have formalized a 10-year alliance that starts with rights to the PD-1, zimberelimab. O’Day also has first dibs on TIGIT and 2 other leading programs, agreeing to an opt-in fee ranging from $200 million to $275 million on each. There’s $500 million in potential TIGIT milestones on US regulatory events — likely capped by an approval — if Gilead partners on it and the stars align on the data. And there’s another $150 million opt-in payments for the rest of the Arcus pipeline.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,900+ biopharma pros reading Endpoints daily — and it's free.

Paul Hudson, Sanofi CEO (Getty Images)

Sanofi CEO Paul Hud­son has $23B burn­ing a hole in his pock­et. And here are some hints on how he plans to spend that

Sanofi has reaped $11.1 billion after selling off a big chunk of its Regeneron stock at $515 a share. And now everyone on the M&A side of the business is focused on how CEO Paul Hudson plans to spend it.

After getting stung in France for some awkward politicking — suggesting the US was in the front of the line for Sanofi’s vaccines given American financial support for their work, versus little help from European powers — Hudson now has the much more popular task of managing a major cash cache to pull off something in the order of a big bolt-on. Or two.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,900+ biopharma pros reading Endpoints daily — and it's free.

File photo (Endpoints News)

In a sting­ing set­back, Pfiz­er’s can­cer block­buster Ibrance flops in key ad­ju­vant set­ting

One of Pfizer’s top, long-running R&D catalysts has gone up in smoke, and it took an $11 billion bite of their market cap in the process.

The monitoring committee determined that Pfizer’s adjuvant study using Ibrance combined with standard endocrine therapy in an adjuvant setting for early-stage breast cancer has officially failed to make the cut. The combo failed to beat the standard alone, tripping over the futility analysis. And the Pfizer team will now wrap the study early after pumping up hopes that their blockbuster cancer therapy could find billions more by proving its efficacy for disease-free survival in a major area — something AstraZeneca just accomplished with Tagrisso to great fanfare.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,900+ biopharma pros reading Endpoints daily — and it's free.